The research-based pharmaceutical industry has gained a positive trend in reputation, as a result of its efforts to fight the Covid-19 pandemic, indicates the Ipsos survey commissioned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). The survey was run in 11 countries and involved 11,000 people aged 18+ living in both high and lower-income countries (USA, UK, India, Brazil, Switzerland, France, South Africa, Japan, Belgium, Germany, Italy).

Particularly appreciated (68%) was the role research-based pharmaceutical companies had in advancing new technologies, i.e more effective medicines or vaccines to tackle the pandemic, as well as possible future public health crises (67%). An high part of respondents (62%) also agreed that research-based pharmaceutical companies are doing all they can to develop solutions to  tackle Covid-19. The high level of investments to discover innovative treatments or cures was acknowledged by 62% of respondents. The same percentage indicated research-based pharmaceutical companies are more effective than governments at discovering new medicines and vaccines.

The survey also indicates a positive perception of the contribution biopharmaceutical companies make to society (60%) and to improving health globally (63%).